Pavan # Swiss biotech Axovant started the year badly, dropping its Alzheimer’s drug intepirdine after it failed in a trial, and it has ended with another flop from a neuroscience drug, nelotanserin. #o , CEO of biotech , has said the company will focus solely on gene therapies after disappointing results from its Alzheimer ’s drug intepirdine and neuroscience offering , nelotanserin . In 2019 , the company is anticipating phase II results from its AXO - Lenti - PD , a treatment for Parkinson ’s disease , and plans to begin clinical trials for AXO - AAV - 1 , which restores normal muscle function in patients with oculopharyngeal muscular dystrophy .
Pavan ##o , CEO of biotech , has said the company will focus solely on gene therapies after disappointing results from its Alzheimer ’s drug intepirdine and neuroscience offering , nelotanserin . In 2019 , the company is anticipating phase II results from its AXO - Lenti - PD , a treatment for Parkinson ’s disease , and plans to begin clinical trials for AXO - AAV - 1 , which restores normal muscle function in patients with oculopharyngeal muscular dystrophy .